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Effectiveness of blended depression
treatment for adults in specialised mental
healthcare: study protocol for a randomised
controlled trial
L. L. Kemmeren1,2*, D. J. F. van Schaik1,2, H. Riper1,2,3,5, A. M. Kleiboer2,3, J. E. Bosmans2,4 and J. H. Smit1,2
Abstract
Background: Internet-based interventions are seen as an important potential strategy to improve accessibility and
affordability of high quality treatments in mental healthcare. A growing number of studies have demonstrated the
clinical efficacy of internet-based treatment for mood disorders, but scientific evidence for the application in routine
specialised mental healthcare settings is limited. Also, little is known about the clinical and health-economic benefits of
blended treatment, where online interventions are integrated with face-to-face treatment of depression in one
treatment protocol. The primary aim of this study is to investigate the clinical and cost-effectiveness of blended
Cognitive Behavioural Therapy (bCBT) for depression, as compared to treatment as usual (TAU) in specialised routine
mental healthcare in the Netherlands. This trial is part of the E-COMPARED project which has a broader perspective,
focussing on primary and specialised care in eight European countries.
Methods/Design: The study is a randomised controlled non-inferiority trial with two parallel conditions: bCBT and
TAU. The blended treatment combines individual face-to-face CBT with CBT delivered through an Internet-based
treatment platform (Moodbuster). This platform includes a mobile phone application, used for ecological momentary
assessments, automated feedback and motivational messages. Weekly alternating face-to-face (10) and online (9)
sessions will be delivered over a period of 19-20 weeks. TAU is defined as the routine care that subjects receive when
they are diagnosed with depression in specialised mental healthcare. Adult patients≥ 18 years old meeting DSM-IV
diagnostic criteria for major depressive disorder will be recruited within participating outpatient specialised mental
healthcare clinics in the Netherlands. Measurements will be taken at baseline and at 3, 6 and 12 months follow-up. The
primary outcome will be depressive symptoms, measured with the PHQ-9 and QIDS. Secondary outcomes include
health-related quality of life, mastery, treatment preference, working alliance, system usability, treatment satisfaction
and possible negative side-effects. Moreover, a cost-effectiveness analysis will be conducted from a societal perspective
and will include both direct and indirect healthcare costs.
Discussion: The results of this study will provide insight into the health and economical outcomes of blended
treatment for depression and give an indication of the value of implementing blended treatment in specialised clinical
settings.
Trial registration: Netherlands Trial Register NTR4962. Registered 05-01-2015.
Keywords: Major depressive disorders, Internet-based intervention, Cognitive behavioural therapy, Blended treatment,
Specialised mental healthcare, Routine practice, Randomised controlled trial, Cost-effectiveness
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Background
Internet-based interventions are seen as an important
potential strategy to improve accessibility to high quality
treatments in mental healthcare. Especially for depres-
sion the need for greater access to cost-effective treat-
ments is stressed out, given the increasing social and
economic burden of this disorder [1]. Depression is
highly prevalent and has a severe negative impact on
wellbeing, quality of life and social and work-related
functioning [2]. The World Health Organisation (WHO)
has predicted that depression will be the foremost over-
all cause of disability in developed countries by 2030 [3].
Despite the presence of several efficacious psychological
and pharmacological treatments, many depressed indi-
viduals remain untreated [4]. It is estimated that in the
Netherlands 40 % of depressed individuals do not receive
or seek adequate care [5]. Deployment of more internet-
based interventions may help bridge this gap.
A growing number of studies have demonstrated the
clinical efficacy and the potential cost-effectiveness of
internet-based treatment for mood disorders in con-
trolled research settings [6–9]. Furthermore, internet-
based treatment with professional guidance has found to
be more effective than unguided delivery [10, 11]. A re-
cent meta-analysis even showed, based on a yet limited
number of studies, that guided internet-delivered cogni-
tive behavioural therapy (iCBT) results in similar overall
effects as regular face-to-face treatment [12].
Only a few studies have directly compared Internet in-
terventions with face-to-face interventions for depres-
sion. In an experimental setting, Wagner et al. [13]
compared similar treatment modules based on cognitive
behavioural therapy (CBT) in a guided online format
with a regular face-to-face format. Another randomised
controlled trial (RCT) compared group-based face-to-
face CBT to guided iCBT [14]. In both non-inferiority
studies no significant differences between the treatment
modalities were found on treatment outcome, indicating
that guided iCBT might be at least as effective as com-
parable face-to-face delivered interventions.
Most of the above mentioned evidence comes from ef-
ficacy trials conducted in controlled research settings.
Whether these promising results can be transferred to
routine clinical practice is less well known. Patient popu-
lations in routine practice are often more heterogeneous
in terms of their characteristics, preferences and comor-
bidity levels than the populations and services in con-
trolled research samples. In a review of Andersson and
Hedman (2013), no RCT and only two uncontrolled
open studies examining the effectiveness on guided
iCBT for depression in routine practice were identified
[15, 16], with medium-large within group effect sizes.
Although available evidence suggests that iCBT may be
as effective in routine practice as it is in randomised
controlled clinical trials [17–20], there clearly is a need
for more effectiveness studies on guided iCBT for de-
pression in routine care. Moreover, most studies so far
were conducted among self-referred depressed individ-
uals from the general population or in primary care. It is
not yet clear whether guided iCBT is a suitable interven-
tion for the more complex patients that are treated in
routine specialised mental healthcare settings.
The question is whether the format of guided iCBT
should be adapted for the application in routine specia-
lised mental health care. In former studies, therapist
support in guided iCBT was usually delivered through e-
mail, chat, telephone or video conference [21]. From a
clinical perspective it seems rational that patients with
more severe and more complex symptomatology of de-
pression as present in routine care, may need face-to-
face interaction [22]. Therefore, a so called ‘blended’
treatment might be more appropriate for these settings,
where online and face-to-face sessions are integrated
into one treatment protocol [23–25]. The face-to-face
part of this treatment ensures that the patient benefits
from a supportive therapeutic relationship and more so-
cial control, that is likely to increase motivation to ad-
here to and complete treatment [26]. Therapists can
help tailor online treatment by meeting specific individ-
ual patient’s needs and wishes, have the opportunity to
probe more deeply and to give immediate responses.
Face-to-face interaction also involves non-verbal cues,
which can be crucial in the communication between pa-
tient and therapist. The online part of blended treatment
means that patients have 24/7 access to treatment mod-
ules, offering more flexibility. In addition, mobile appli-
cations can support the therapy by real-time monitoring
of patient’s state (“ecological momentary assessment”)
and by personalised feedback based on user data (“eco-
logical momentary intervention”) [27–29]. Blending on-
line and mobile components with face-to-face therapy
could improve patients’ active participation in the treat-
ment, increasing self-reliance and self-management
competencies, which subsequently may contribute to
better long term results [13]. By extending the reach of
the therapy into the daily life of patients, the number of
face-to-face sessions required could be reduced, result-
ing in a decrease of costs. Additionally, waiting times
caused by limited availability of clinicians could be re-
duced when part of the face-to-face sessions are replaced
by online treatment, which means therapists can treat
more patients in a given time period. Also, other chal-
lenges patients meet when seeking traditional care can
be tackled with online treatment, such as inconvenience
of session times, travel time and -costs or mobility issues
[30, 31].
Until now, only a few studies have investigated
blended treatment formats [32–34]. Preliminary findings
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are promising, indicating that blended treatment can be
effective in the reduction of depressive symptoms. How-
ever, to date, no data are available on the effectiveness of
blended depression treatment compared to traditional
face-to-face therapy in routine specialised mental health-
care. To investigate whether blended treatment for de-
pression in routine (specialised) mental health care may
be an attractive solution to overcome the aforemen-
tioned challenges, the European Commission has
granted a large European study (the E-COMPARED pro-
ject: ‘European Comparative Effectiveness Research on
Internet-Based Depression Treatment’), in which eight
European countries will conduct a similar RCT to assess
the clinical and cost-effectiveness of blended treatment
for depression compared to treatment as usual (TAU)
[35]. The proposed study is part of the E-COMPARED
project and focusses on the RCT in the Netherlands.
Trial objectives
The overall objective of E-COMPARED is to provide
mental health care stakeholders including policymakers,
patients, health care professionals, health insurers and
mental health service providers with evidence-based in-
formation and recommendations about the (cost-)effect-
iveness of blended treatment for depression. Within E-
COMPARED data will be pooled across eight participat-
ing countries, with a total of 1200 participants. This
large clinic based sample generates statistical power to
analyse treatment impact in terms of depression out-
comes and cost-effectiveness as well as in terms of mod-
erators and mediators of outcome, thereby investigating
what treatment works best for whom [35, 36].
This protocol describes the RCT in the Netherlands.
The primary objective is to evaluate the clinical and
cost-effectiveness of blended Cognitive Behavioural
Therapy (bCBT) for adults with a diagnosis of Major
Depressive Disorder (MDD), as compared to treatment
as usual (TAU). We expect the blended treatment to be
at least as effective as the regular treatment for depres-
sion in routine specialised mental healthcare (non-infer-
ior), but that the blended form can be offered at lower
costs than TAU. Furthermore, the study aims to explore
which patients are likely to benefit from this particular
kind of treatment delivery and how to tailor blended de-
pression treatment to individual patients, related to their
characteristics.
Methods and design
Study design
This study is a two-arm parallel non-inferiority rando-
mised controlled trial, comparing internet-based bCBT
to routine care that patients receive when treated for
MDD in outpatient specialised mental healthcare (TAU).
The protocol for this study has been approved by the
Medical Ethics Committee of the VU University Medical
Centre (registration number 2015.078).
Inclusion and exclusion criteria
In order to be eligible, participants must be ≥ 18 years
old, have a primary diagnosis of Major Depressive Dis-
order according to DSM-IV criteria as confirmed with
the MINI International Neuropsychiatric Interview
(M.I.N.I) [37], and have a score above 5 on the Patient
Health Questionnaire (PHQ-9) [38]. Participants will be
excluded if meeting any of the following criteria: 1) hav-
ing acute risk of suicide, assessed clinically by trained in-
terviewers with the M.I.N.I.; 2) having serious
psychiatric co-morbidity (e.g. bipolar disorder, psychotic
illness or substance dependence) that requires alterna-
tive treatment, primary to the treatment of MDD; 3)
participating in other psychological treatment for de-
pression, parallel to the intervention treatment of the
study; 4) insufficient comprehension of the spoken and
written Dutch language; 5) not having access to a com-
puter or tablet with internet; 6) not willing to carry an
Android smartphone during the treatment period (made
available by the research team when they do not have an
Android smartphone themselves); 6) not willing to be
randomly assigned to one of the two treatment groups,
bCBT or TAU.
For applicants that are at high risk for suicide, relevant
information and telephone numbers are provided and
therapists are notified such that standardised procedures
within the participating mental healthcare centres can
be followed. When stabilised, the patient can still poten-
tially be eligible to participate.
Recruitment
Participants will be recruited within participating specia-
lised mental healthcare centres in the Netherlands. For
specialist mental healthcare, patients need a referral
from a general practitioner or primary mental healthcare
professional. Referred patients first undergo an intake
interview by mental healthcare specialists, who deter-
mine the diagnosis and treatment plan. During the in-
take procedure, clinicians will ask all new patients with a
primary diagnosis of MDD if they are interested to par-
ticipate in the study, and provide them with a letter con-
taining detailed information about the study and an
informed consent form. Patients who have agreed to be
approached by the researchers, will be contacted within
a week by telephone and after going through the study
information asked whether they are willing to partici-
pate. If affirmative, the researcher first screens whether
some major study requirements are fulfilled (sufficient
command of the Dutch language; no other parallel
psychotherapeutic treatment for depression; having ac-
cess to the internet; willing to carry an Android
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smartphone during the treatment period; and willing to
be allocated randomly to the treatment condition) and
the patient will be asked to sign the informed consent
form and return it by post. If the initial criteria are ful-
filled, the M.I.N.I. diagnostic interview will be conducted
by a trained interviewer by telephone to determine de-
pression status and co-morbidity. When eligible, and
after receiving the signed informed consent, the re-
searcher sends an e-mail to the patient containing an in-
vitation with a link to fill out the online questionnaires.
After completion of the baseline assessment, the patient
is randomised to either bCBT or TAU. Patients are in-
formed about the randomisation outcome by the re-
searchers via telephone and therapists via e-mail.
Treatment starts as soon as possible after the inclusion,
preferably within two weeks. Participants will be in-
formed that they can withdraw from the study at any
time, without any statement of reasons and without any
consequences for their subsequent treatment.
Patients who are not eligible to participate will be noti-
fied and remitted to regular treatment trajectories within
the participating mental healthcare centres.
Randomisation and blinding
Randomisation will take place at an individual level
stratified by mental healthcare centre. The allocation will
be conducted centrally at the VU Amsterdam by an in-
dependent team of researchers which is not involved in
the trial. A computerised random number generator
[39] is used to produce the allocation scheme with an
allocation ratio 1:1. Subjects will be randomised into
two groups: bCBT or TAU. The allocation is con-
cealed, researchers and clinicians will be unknown to
the randomisation scheme. Blinding for the treatment
is not possible as it will be clear to both therapists
and patients when the treatment is blended or not.
However, the assessor conducting the M.I.N.I. at
follow-up will be blinded to treatment status. The
flowchart of the study is presented in Fig. 1, accord-
ing to CONSORT guidelines [40].
Blended intervention
The treatment manual is based on evidence-based Cog-
nitive Behavioural Therapy (CBT) protocols imple-
mented in routine practice [41] and recommendations
in treatment guidelines for depression [42, 43]. The
blended model provides CBT by integrating individual
face-to-face (FTF) sessions and online sessions, sup-
ported by a smartphone application for the real-time
monitoring of patients’ state in their natural environ-
ment (ecological momentary assessment: EMA).
Through the mobile phone application, patients will also
get automated motivational messages stimulating en-
gagement on the platform as well as reminders to
encourage treatment-related activities and improve com-
pliance (ecological momentary intervention: EMI).
Patients receive ten FTF and nine online sessions over
a period of 19–20 weeks, adhering to the usual time
frame for the face-to-face CBT. The FTF and online ses-
sions are weekly alternated (ratio 50/50). Communica-
tion between therapist and patient in-between the FTF
sessions is asynchronous. The online part of the blended
intervention is called “Moodbuster” [44].
Online treatment platform
Moodbuster is based on the ICT4Depression platform
(ICT4D), developed in a previous European FP7 project
and applied in three small-scale clinical feasibility pilot
trials [29, 45]. ICT4D was originally developed as a self-
help system and is for the current project adapted to fit
the blended format where therapist support is included.
Previous to the proposed trial, a technical pilot of
Moodbuster was conducted to ensure good system sta-
bility, responsiveness, functionality and usability in live
trials. The ICT-platform Moodbuster is currently avail-
able in five languages: English, Dutch, German, Polish
and French.
The platform consists of 1) a patient portal: an online
treatment environment for patients, with access to the
treatment modules, homework exercises, mood graph,
calendar and messaging system, 2) a therapist portal: a
back-office for caregivers to monitor their patients and
provide written feedback on exercises and progress in a
secure way, and 3) a mobile application for real-time
monitoring of mood state, cognitions, activities, social
interaction, and sleep of the patient, as well as providing
automated tailored reminders and motivational mes-
sages. Patients and therapists access the platform with a
personalised log-in. Figures 2 and 3 show screenshots of
the Moodbuster platform.
Blended treatment protocol
Moodbuster contains an introduction module and six
online treatment modules that are applied as integrated
components of the FTF sessions within the blended
treatment protocol. All treatment modules have the
same structure, starting with an introduction and video
about the content and purpose of the module, followed
by didactical parts and exercises to apply the learned
theory to own situations, and ending with a question-
naire assessing symptom severity and evaluation of the
module. Patients work on one module at a time and get
gradual access to the modules. The introductions of the
modules are accessible at all time, but before entering a
new module the patient has to confirm that the choice
to activate that module was made in accordance with
the therapist.
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The blended treatment starts with the Introduction
and Psycho-education module and ends with Relapse
prevention. The order of the intermediate modules –
Cognitive restructuring, Behavioural activation, Problem
solving skills and Physical exercise – may vary, depend-
ing on the needs and preferences of the patient. The
modules Cognitive restructuring and Behavioural activation
are obligatory, as being part of the core components of the
treatment. Therapists are required to include all four
elements of CBT (psycho-education, cognitive restruc-
turing, behavioural activation and relapse prevention),
but are free to decide how many sessions are spent
Fig. 1 Study flowchart
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Fig. 2 Moodbuster website: homepage of the patient portal
Fig. 3 Moodbuster website: patient profile on therapist portal
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on each module. On completion of treatment, patients
can continue to access Moodbuster to reread information
and look up or repeat homework exercises.
Guidelines for the 45 min FTF sessions are to monitor
and discuss depression symptoms based on mood rat-
ings on the mobile phone, to review patients experiences
with the homework exercises and the given feedback
and to explain rationale and exercises within the current
or upcoming module. The FTF sessions follow up on the
CBT modules where content and exercises can be dis-
cussed in more depth, but also gives the therapist the
opportunity to respond to the individual patient’s needs.
Within the online sessions the patient works through a
module and completes homework exercises. The therap-
ist provides the patient with personalised written feed-
back on progress and content of exercises they have
completed on the online treatment platform. The feed-
back is given at a scheduled time in-between the FTF
sessions, via the Moodbuster messaging system. Provid-
ing online feedback will take therapists approximately
15 min. The mobile phone application will be used for
EMA: the real-time monitoring of patients state in their
natural environment. Patients will be prompted to rate
their mood state, cognitions, activities, social interaction
and sleep on a scale from 0–10 (from low to high). The
EMA assessment questions and schedule are presented
in Table 1. On the mobile application, patients will also
receive automated motivational text messages to keep
engaged with Moodbuster (rate mood and log in on plat-
form), as well as reminders for scheduled activities
within the modules and appointments with their therap-
ist (EMI).
Therapists
Either licenced CBT therapists or CBT therapists in train-
ing who work under supervision of an experienced CBT
therapist will provide the blended depression treatment.
All will receive extensive training on how to deliver the
treatment (use of platform, skills for written feedback,
blended protocol). To ensure treatment fidelity (1) a de-
tailed treatment manual is available to guide therapists
through the treatment, (2) regular supervision is provided
between the therapists and the research coordinator and/
or CBT supervisor and (3) therapists will fill in fidelity
questionnaires after each session registering the (module)
interventions used and the length of the contact. The
number and frequency of sessions will be derived from
the Electronic Patient Record Form and therapists’ activ-
ities on the platform will be assessed through track and
change functionalities (log files).
Treatment as usual
TAU is defined as the routine care that subjects receive
when they are treated for depression in routine specialised
outpatient mental healthcare. The type of treatment can
vary and may consist of face-to-face psychotherapy
(mainly CBT, interpersonal psychotherapy (IPT) or sup-
portive therapy), antidepressant medication, running ther-
apy, or a combination of these. We will not interfere with
TAU but we will monitor carefully treatment utilisation
through patient records, self-reported healthcare utilisa-
tion and fidelity checklist from therapists (see assess-
ments). In both arms patients may receive medication; in
this sense usual care is being followed.
Assessments
Measures will be taken at baseline and at 3, 6 and
12 months after baseline. The diagnostic interview
(M.I.N.I.) at baseline will be conducted by telephone by
trained interviewers. At 12 months follow-up the de-
pression, anxiety and PTSD sections of the M.I.N.I. will
be assessed again by telephone by an interviewer blinded
to treatment allocation. All other assessments will be
performed online via a link to the self-report question-
naires sent by e-mail. Table 2 provides an overview of
the measures and their time of assessment.
Table 1 EMA assessment questions and schedule
Timing Concept Question
Full EMA diary Morning diary Sleep How well did you sleep last night?
Mood How is your mood right now?
Worrying How much do you worry at the moment?
Self-esteem How do you feel about yourself right now
Evening diary Mood How is your mood right now?
Worrying How much do you worry at the moment?
Self-esteem How do you feel about yourself right now
Enjoy activities How much did you enjoy activities today?
Social contacts How much were you involved in social interactions today?
Pleasant activity level To what extent did you accomplish pleasant activities today?
Mood rating Random Mood How is your mood right now?
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Outcome measures
Primary outcome measure
The primary outcome measure is symptoms of depression
as assessed with the Patient Health Questionnaire-9
(PHQ-9) [46]. The PHQ-9 is a nine-item mood module
that can be used to screen and to diagnose patients with
depressive disorders. The 9 items are each scored on a
0–3 scale, with the total score ranging from 0–27 and
higher scores indicating more severe depression. The
PHQ-9 has shown to have good psychometric properties
[47, 48].
The Quick Inventory of Depressive Symptomatology
Self-Report (QIDS-16-SR) is used in addition to the
PHQ-9, because this measure is more often used (espe-
cially in specialised mental healthcare) and therefore
makes better comparison with other studies possible.
The QIDS assesses depression severity and consists of 16
items (each item scores 0–3, total range 0–48), with
higher total scores being indicative of a higher severity
of depressive symptoms. The QIDS includes symptom
domains of MDD based on DSM-IV and Research Diag-
nostic Criteria (RDC). The QIDS has shown highly ac-
ceptable psychometric properties, with internal
consistency of α = .86 [49]. The cut-off points of 6, 11,
16 and 21 represent the thresholds for mild, moderate,
severe and very severe depression, respectively.
Secondary outcome measures
A diagnosis of depression will be assessed with section A
and B of the MINI International Neuropsychiatric Inter-
view (M.I.N.I.) version 5.0, a structured diagnostic inter-
view based on the Diagnostic and Statistical Manual of
Mental Disorders (DSM-IV) and on International Classi-
fication of Diseases (ICD-10) criteria [37]. In comparison
with the patient-rated version of the SCID, the M.I.N.I.
achieved a good Kappa score of 0.84 with a sensitivity of
0.96 and a specificity of 0.88 in diagnosing Major
Depressive Disorder (MDD) [50].
The full M.I.N.I., with exception of section M (An-
orexia Nervosa), N (Bulimia nervosa), and P (Antisocial
personality disorder), will be conducted at baseline (T0)
to determine lifetime and current depression, as well as
current comorbid psychiatric. At 12 month follow-up
(T3), the depression, anxiety and PTSD sections of the
M.I.N.I. will be assessed again, covering the past
12 months.
Demographic variables including age, sex, ethnicity,
marital status, educational level and employment status,
as well as history of treatment for mental health prob-
lems will be assessed at baseline. In addition, patients
will be asked about treatment preference, indicating
which treatment alternative they prefer (bCBT or TAU)
before being allocated to one of the two conditions.
Table 2 Overview of measures
Variable Instrument T0* T1* T2* T3*
Measures taken from patient
Demographics (patient characteristics) X
Current and history of treatment X
Diagnosis of depression and comorbid disorders M.I.N.I. 5.0 X X
Depressive symptoms PHQ-9 X X X X
Depressive symptoms & severity QIDS-SR-16 X X X X
Health related well-being (QALY) EQ-5D-5L X X X X
Health care uptake and productivity losses TIC-P TIC-P X X X X
Sense of mastery SOMS X X X X
Treatment preference X
Patient expectancy CEQ X
Therapeutic alliance WAI-SF-PT X
Technology alliance WAI-Online Therapya X
Client satisfaction with treatment CSQ-8 X
Satisfaction with the online program SUS SUSa X
Possible negative side-effects INEP X
Measures taken from therapist
Therapeutic alliance WAI-SF-THb X
Satisfaction with the online program SUSc X
aOffered to condition receiving blended treatment only
bHas to be completed for each patient. Offered at the same time point as T1 assessment of the patient
cHas to be completed once per therapist after completion of the first blended treatment
*T0 refers to baseline and T1, T2 and T3 to the 3, 6 and 12 month questionnaires
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Patients’ expectancy of treatment will be assessed after
randomisation with the Credibility and Expectancy
Questionnaire (CEQ). This questionnaire consists of six
items measuring expectancies toward the therapy and the
credibility of treatment options. The items are scored on
one of two scales, one 9-point Likert scale ranging from 0
(not at all) to 9 (absolutely) or a continuous scale ranging
from 0 % (not at all) to 100 % (absolutely). The sum score
on credibility and expectancy can vary between 3 and 27,
with higher scores being indicative of more positive atti-
tudes. Both factors (credibility and expectancy) have
shown to be stable across different populations, with high
internal consistency within each factor [51].
Locus of control will be assessed with the 5-item version
of the Sense of Mastery Scale [52], with proven good re-
liability [53]. Questions are scored on a Likert-scale ran-
ging from 1 (‘totally disagree’) to 5 (‘totally agree’). The
total score ranges from 5 to 25, with higher scores being
indicative of a higher degree of perceived control. The
Sense of Mastery Scale will be administered at all time
points (T0-T3) to assess changes in locus of control.
Patient’s satisfaction with the treatment will be
assessed with Client Satisfaction Questionnaire (CSQ-8),
used to measure global patient satisfaction [54]. The
questionnaire consists of 8 items that are measures
on a 4-points scale. Total scores range from 8 to 32,
with higher scores being indicative of higher levels of
satisfaction. The CSQ-8 has high internal consistency
of α = .93 [55].
Satisfaction with the online platform will be evaluated
with the System Usability Scale (SUS), a simple 10-item
questionnaire giving a global view of subjective assess-
ments of usability of a technology system [56]. All items
are measured on a 5-point Likert scale ranging from
‘strongly disagree’ to ‘strongly agree’. Total SUS scores
have a range from 0–100. The questionnaire was found
to be reliable and robust [57]. The SUS has to be com-
pleted by patients receiving bCBT only, and once per
therapist three months after starting with their first
blended treatment.
The therapeutic alliance between therapists and pa-
tient will be assessed with the short version of the
Working Alliance Inventory (WAI-SF) [58], Dutch ver-
sion [59]. The WAI-SF is a 12-item self-report question-
naire with responses on a 5-point Likert scale ranging
from’never or rarely’ to ‘very often’. The questionnaire
covers three dimensions of working alliance: 1) thera-
peutic goals, 2) tasks, and 3) bond. The subscales have
shown to have good internal consistencies (α > .80). Both
the patient and the therapist version of the questionnaire
will be administered at T1, to determine the quality of
the therapeutic alliance.
The alliance between the patient and technologies will
be assessed with an adapted version of the WAI: the
Working Alliance Inventory – Online Therapy, developed
by Labpsitec (Labority of Psychology and Technology).
The items address goals and tasks agreement with the on-
line treatment program, and not with the therapist.
To assess possible negative side-effects of the treat-
ment, the Inventory of Negative Effects of Psychotherapy
(INEP) [60] will be administered at T2 (6 months after
baseline). The version used in this study consists of 15
items, assessing a range of common changes participants
experienced in line with their therapy, concerning their
social and work environment. The following domains
are covered: negative interpersonal changes, negative ef-
fects in an intimate relationship, family/friends, per-
ceived dependence from therapist, stigmatisation. All
items are rated on a 4-point Likert scale. For each item,
respondents also state whether they attribute the adverse
effects on the therapy or on other circumstances. Only
item scores of those negative effects that were attributed
on the therapy are added to the total score. Higher total
scores indicate more negative effects. The INEP shows
an internal consistency of α = 0.85 [60]. For the use in
this study, the questionnaire was translated by the
forwards-backwards method, i.e. the questionnaire was
first translated from English into Dutch by two persons
who reached consensus by discussion. Next, the ques-
tionnaire was translated back to English and was com-
pared with the original questionnaire.
Economic evaluation
Quality of life will be determined with the five-level ver-
sion of the EuroQol (EQ-5D-5L), a self-report question-
naire assessing the health related well-being of
participants [61]. The questionnaire consists of five
items: mobility, self-care, daily activities, discomfort and
mood state. Each item has five response categories ran-
ging from ‘no problems’ to ‘a lot of problems’ [62]. Fur-
thermore, this scale contains a visual analogue scale
concerning health state. The EQ-5D-5L health states will
be converted to utility scores using the Dutch tariff.
Quality-adjusted life-years (QALYs) will be calculated by
multiplying the utility of a specific health state by the
time spent in that health state. Changes in health states
between measurements will be linearly interpolated. The
EQ-5D-5L holds acceptable levels of content validity
[63] and has demonstrated valid redistribution, reduced
ceiling, and improved discriminatory power and conver-
gent validity compared to the EQ-5D-3L [64].
Health care utilisation and productivity losses due to
illness will be measured using an adapted version of the
Trimbos and iMTA Questionnaires on Costs Associated
with Psychiatric Illness (TiC-P), a self-report question-
naire consisting of two different parts that can be ad-
ministrated separately [65]. Part I will be used to assess
the participants’ healthcare utilisation and medication
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use. Part II (short form Health and Labor Questionnaire;
SF-HLQ) consists of 11 items measuring lost productiv-
ity costs resulting from absenteeism (being absent from
work because of illness) and presenteeism (being present
at work while ill which may lead to reduced efficiency).
Engagement and usage measures for bCBT
Activities on the platform such as number of visits, time
in-between logins and number of messages exchanged
between patient and therapist, will be assessed through
track and change functionalities (log files). Data on how
patients use online modules (frequency, duration, order,
completion), how they rate them and to what extent
they adhere, will also be obtained through usage statis-
tics on the Moodbuster online treatment platform.
Patients receiving the blended treatment will as part of
the treatment protocol additionally fill out the PHQ-8 at
the end of each module, for monitoring treatment outcome
(i.e., all items on the PHQ-9 scale except the ninth item).
As this data is being gathered in a self-administered fashion
and direct action on positive responses on the ninth item
inquiring “thoughts that you would be better off dead or of
hurting yourself in some way” is not feasible, it was chosen
to exclude this item. Patients are instructed to use existing
services of the mental health care organisations when they
feel the need to contact a doctor or a therapist outside
working hours. The PHQ-8 has similar operating character-
istics as the PHQ-9 (sensitivity, specificity, and positive pre-
dictive value), regardless of the threshold [38].
Sample size
For the European study as a whole, the sample size cal-
culation is based on the non-inferiority design and cal-
culated for the primary clinical outcome symptoms of
depression. The non-inferiority margin was set at
ΔCohen’s d = 0.20, which is a conservative estimate of
the subjective minimal important difference that is no-
ticeable by patients [66]. To determine that there is no
difference between blended depression treatment and
TAU on the primary clinical outcome, a total of 1052
patients is required to be 90 % certain (power of .90)
that the lower limit of the two sided 95 % confidence
interval will be above the non-inferiority limit of Cohen’s
d = -0.2. To allow for expected drop-out and variation
between settings, the total number of participants to be
recruited will be 1200.
For the current trial in the Netherlands we aim to in-
clude 156 participants (78 per arm). This sample size
will be sufficient to be 80 % sure (i.e. power = 1-ß = 0.80)
that the lower limit of a one-sided 95 % confidence
interval (or equivalently a 90 % two-sided confidence
interval) will be above a non-inferiority limit of -0.4 if
we assume that there is no difference between the stand-
ard and blended depression treatment. A margin of 0.4
was judged acceptable, as this range of small to moder-
ate difference in effect size will not result in clinically
important differences [67].
Planned statistical analyses
In a non-inferiority trial, the study objective should be
achieved in both the intention to treat and per-protocol
population [68]. Analysis will be based on intention to
treat (ITT) design, including all participants randomised
in the study. Participants will be encouraged to provide
assessment data, regardless of treatment adherence.
Additionally, per-protocol (PP) analysis will be con-
ducted, including only participants who followed the
treatment protocol of the assigned treatment. Non-
inferiority should be demonstrated also in the PP ana-
lysis, because ITT tends to dilute differences [69]. All
analyses will be performed using the Statistical Package
for the Social Sciences (SPSS), version 20.0.
Economic evaluation
We will perform an economic evaluation from societal
perspective, conducting a cost-effectiveness analysis
(CEA) and cost-utility analysis (CUA). The CEA will be
based on treatment response, defined as a 50 % pre-post
reduction of QIDS-SR depressive symptoms [49]. The
CUA will be conducted using quality adjusted life years
(QALYs) as a generic measure of health gains. Multiple
imputation using chained equations (MICE) will be used
to impute missing cost and effect data. Predictive Mean
Matching will be used to account for the skewed distri-
bution of costs [70]. Variables that will be included in
the multiple imputation model are variables related to
missingness, variables related to costs and effects at
12 months of follow-up and all variables included in the
analysis model. The number of imputations will be in-
creased until the fraction of missing information (FMI)
is 5 % or less [70]. The completed datasets will be ana-
lysed separately and pooled using Rubin’s rules [71].
Multilevel analyses with adjustment for mental health
care institution will be done to estimate differences in
costs and effects between bCBT and TAU while correcting
for potential effect modifiers and confounders. Incremen-
tal cost-effectiveness ratios (ICERs) will be calculated by
dividing the difference in costs by the difference in effects.
Bias-corrected and accelerated bootstrapping with 5000
replications will be used to estimate statistical uncertainty.
Bootstrapped cost-effect pairs will be plotted on cost-
effectiveness planes (CE planes) to visualize the uncer-
tainty surrounding the ICERs. Moreover, for decision-
making purposes cost-effectiveness acceptability curves
will be estimated showing the probability that bCBT is
cost-effective in comparison with TAU at a range of differ-
ent ceiling ratios. Finally, to test the robustness of our
findings, sensitivity analyses will be performed. First, the
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economic evaluation will be conducted from a healthcare
perspective. Secondly, a per protocol analysis will be done
in which only participants completing the bCBT treat-
ment protocol will be included.
Clinical evaluation
Independent t-tests and χ2-tests will be used to estimate
between-group differences in demographics and pre-
treatment measures at baseline. Outcomes on continu-
ous outcome variables at T1, T2 and T3 will be analysed
via mixed-model analyses, with participants as random
effects, and time (T1-T3), group (bCBT vs. TAU) and
time x group as fixed effects, with baseline scores as a
single covariate. To assess the magnitude of treatment
effects, Cohen’s d effect sizes [72] for each time point
will be calculated by dividing MM parameter estimates
of fixed effects at each post-treatment assessment by the
pooled standard deviation of baseline scores. Effect sizes
under 0.2 are deemed to be small, 0.5 to be moderate
and 0.8 to be large [72].
Differences in response and remission rates, as well as
adherence rates will be examined using t-tests and χ2-
tests. In addition, moderator analysis will be conducted
for demographic variables such as gender, age, educa-
tional level, partner status, employment status, as well as
treatment and patient characteristics.
Discussion
The aim of this study is to evaluate the clinical and cost-
effectiveness of blended CBT where face-to-face treatment
is combined with internet and mobile technologies, as
compared to treatment as usual for adults with MDD in
routine specialised mental healthcare. Keeping depression
treatment accessible, feasible and affordable is of high im-
portance, considering the large individual and economic
burden of this disease [1, 2]. The study described in this
paper is the trial conducted in the Netherlands as part of
E-COMPARED. The results of this study will provide
insight into the health-economical outcomes of blended
treatment and give an indication in the value of imple-
menting blended treatment into routine specialised men-
tal healthcare.
Although previous findings have shown similar effect
of guided iCBT compared to traditional FTF treatment
[17, 19], the current study will give an answer to the
question whether this also holds for bCBT in more com-
plex and severely depressed patients in specialised care,
as well as whether bCBT is more cost-effective than
regular depression treatments. Given that the number of
required FTF sessions is reduced by replacing them with
online sessions, it is assumed that bCBT might lead to
cost savings. At the same time, waiting lists could be di-
minished as therapists can treat more patients in a given
time period. The quicker treatment can start, the sooner
people suffering from depression do recover and the
sooner they are able to participate in society. Down the
road, this could have a positive impact on the social eco-
nomic consequences of depression seen that productivity
losses due to the illness (absenteeism and presenteeism)
is often the biggest expense [73, 74].
A major strength of the present study, is that it is one
of the first to assess blended treatment instead of
internet-based interventions used as standalone or add-
ons, in the treatment of depression in routine practice.
The assumption underlying the integrated approach
within blended treatment, is that the benefits of online
treatment are combined with the advantages of FTF
therapy. However, many questions regarding a blended
treatment format are still unanswered, e.g. on how to
best blend the two modes of delivery, on program struc-
ture and flexibility or on frequency and content of ther-
apist support [24, 25]. This study will contribute in
yielding meaningful answers to these questions. It will
also become clear to what extent the blended interven-
tion suits patients in specialised mental healthcare, by
looking at adherence, dropout and satisfaction with
treatment.
Another strength is the innovative character: the
blended treatment in our study also includes a mobile
component, making ecological momentary assessment
and intervention techniques possible. The real-time
monitoring of patient’s state can enhance insight into
meaningful patterns of the depression, aspects contribut-
ing to changes in mood and influence of treatment inter-
ventions, acting as an intervention itself. With EMI,
treatment engagement and completion of therapy-
related homework tasks can also actively be encouraged,
for example by sending reminders for scheduled activ-
ities. Adding these new possibilities, can aid in personal-
izing treatment and optimizing adherence [27, 75].
A further strong feature of this trial is that patients
with comorbidity will only be excluded when alternative
treatment for that comorbid condition is required pri-
mary to the treatment of MDD, similar to usual proce-
dures in the treatment indication for depression. This
will maximize the external validity of the trial and reflect
the heterogeneity and complexity of the patient popula-
tion in specialised routine mental healthcare settings.
Also, we will not interfere with current practice within
the TAU group. By following the usual care paths for de-
pression, generalizability to routine practice is strength-
ened. This strength can also be regarded as a
limitation, as TAU cannot be foreknown and is ex-
pected to be heterogeneous. However, this study is
designed to be a pragmatic trial and it is our aim to
compare the effectiveness of bCBT with current usual
care. TAU will be monitored carefully, to control for
potential confounding effects.
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The current study also presents us the challenge of
providing a new treatment modality within everyday
practice. To aid the implementation and ensure treat-
ment fidelity, therapists receive extensive training on
how to deliver bCBT, (technical) support is offered by
the research team and therapists are provided with a
treatment manual. Taking into account the heterogeneity
of the disorder, our blended protocol allows for some
flexibility, e.g. in the order of the modules and time
spent on each module. By keeping track of activities on
the Moodbuster platform, we will be able to get insight
into what happens during therapy to increase knowledge
on the suitability and applicability of blended depression
treatment for patients in specialised clinical practice.
Overall, this study will provide mental healthcare
stakeholders evidence-based information on the clinical
and cost-effectiveness of bCBT and recommendations
on how bCBT can be integrated into routine specialised
mental healthcare settings.
Trial status
The trial is in the on-going recruitment phase. Recruitment
started in July 2015.
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The protocol for this study has been approved by the
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